glp 1 for mash Resmetirom and GLP-1 agonists MASH: complementary rather than exclusive GLP-1 Fatty Liver MASH Approval:
Description
Socioeconomic aspects of incretin-based therapy
In a meta-analysis of 60 studies involving 60,077 T2D patients, GLP-1RAs marginally reduced the UACR in comparison to placebo and other antidiabetic agents, but resulted in no clinically relevant changes in eGFR ( Renoprotective Mechanisms of GLP-1RAs Experimental studies to elucidate the beneficial effects on DKD have been extensively reported
These ongoing lawsuits allege that the drug has caused life-threatening injuries, prompting patients to seek compensation for medical costs, pain and suffering, and more
Ozempic manufacturer Novo Nordisk claims semaglutide is a safe and well-tolerated medication, with nausea as the most common adverse event
A similar study by Pondugula et al
